Study at a glance
What did studies examine about vitamin D and depression?
A small trial tested vitamin D3 alongside usual treatment in adults with depression. A separate population study examined childhood abuse history, vitamin D status, genetic differences and depression. These studies asked different questions. They did not demonstrate one complete pathway linking stress, inflammation, serotonin and mood.
Did vitamin D improve depression scores in the trial?
After eight weeks, depression questionnaire scores improved more in the vitamin D group than with placebo. Three measured blood signs of inflammation did not show significant treatment effects. The reported analyses included 28 people per group, mostly women, but participant totals and exclusions were inconsistently described. Depression was an additional outcome, rather than the trial’s main outcome. Starting vitamin D levels differed, and most participants were not severely deficient. The result is a promising symptom finding with substantial uncertainty, not proof of recovery for every patient.
How were childhood abuse, vitamin D and depression linked?
Exploratory analyses suggested that links among abuse history, genetic grouping and current symptoms differed by vitamin D status. The matching analysis of lifetime depression did not show a significant result. A genetic marker used in another analysis was a weak substitute for measured vitamin D. Some reported statistics were inconsistent, and the different analyses did not amount to exact independent confirmation.
Do these findings establish a supplement plan for depression?
The population findings cannot show what supplements would do, and other influences or early illness could affect the associations. The trial did not establish that inflammation was irrelevant; it measured only three markers in the blood. Neither study directly demonstrated an effect working through brain serotonin or stress hormones. Together, they do not establish a personalised supplement plan, a treatment threshold or a proven method of preventing depression.
Read the full article below ↓A small vitamin D trial reported a larger improvement in depression symptoms without a significant change in three measured inflammatory markers. A separate population study found exploratory patterns involving childhood abuse, vitamin D status and genetic variation. Together they show why mood research needs several kinds of evidence, while leaving a causal stress-to-inflammation-to-serotonin pathway unproven. For the shorter account, see Vitamin D, Depression Symptoms and Stress-Related Risk Patterns: Study Summary.
This is a VD3FL analysis, not either original publication. The two principal papers, the Bonk supplement and the Kaviani protocol and registry were reviewed. The studies used different people, designs and outcomes.
Two questions that should remain separate
Kaviani and colleagues tested an intervention in outpatients with depression. Bonk and colleagues examined associations among existing characteristics in two population samples. The trial can address the effects of the assigned regimen within its limitations. The population study can identify patterns worth testing, but cannot show what would happen if the participants took a supplement.
Both belong within Vitamin D and Mood. Their findings should nevertheless retain their separate denominators and outcomes. An improvement in a symptom questionnaire, a lifetime diagnosis and a statistical interaction are different results. Combining their narratives does not turn the two studies into consecutive experiments on one demonstrated biological pathway.
The depression trial: setting and treatment
The eight-week trial took place at Baharloo Hospital in Tehran in 2018-2019. Participants were aged 18-60 and had mild or moderate depression identified using psychiatric assessment and the Persian Beck Depression Inventory II, or BDI-II. The analysed sample contained 50 women and six men, with a mean age of about 43.
The assigned intervention was 50,000 IU cholecalciferol every two weeks, compared with oral paraffin placebo. Participants continued their usual medication and were asked to maintain diet and activity; the report does not establish a uniform antidepressant regimen for everyone.
The investigators describe a double-blind trial, although the project head knew allocation. Allocation-concealment details were limited. Reminder calls, pill counts and self-report supported high reported adherence among retained participants. The absence of reported adverse-drug complaints over eight weeks establishes neither long-term safety nor suitability for other patients.
Who was actually analysed?
There is a material inconsistency in the trial’s participant reporting. The abstract and methods describe 56 randomised participants, but the published flow diagram shows 69 randomised, 36 assigned to vitamin D and 33 to control. After eight and five exclusions respectively, the outcome tables contain 28 participants per group.
The authors describe their approach as intention-to-treat, but the report does not explain how outcomes for all 13 excluded participants were retained or imputed. The safest account is therefore 28 per arm in the reported analyses, with an unresolved discrepancy between the text, flow diagram and claimed analysis population. Attrition could affect the comparison if those lost differed in ways related to response.
The sample was not predominantly severely vitamin D deficient. At baseline, mean 25-hydroxyvitamin D was 87.1 nmol/L in the intervention group and 73.64 nmol/L in control. Under the study’s definitions, one versus seven participants were deficient. A baseline P value near .05 does not demonstrate that starting status was identical between groups.
Symptoms improved, while selected inflammatory markers did not
Mean BDI-II fell from 23.86 to 12.11 in the intervention arm and from 21.79 to 18.18 in control. The reported mean changes were -11.75 and -3.61 points. Subtracting those changes gives an 8.14-point difference, a calculation from the published means rather than an adjusted treatment estimate with a reported confidence interval.
The paper reports P=.003 for the between-group depression result, but the prose associates that value with change while Table 2 labels the corresponding column “After”. The direction of the symptom result is clear; its exact statistical presentation is less clear. Group-average scores also cannot establish how many individuals remitted, recovered or experienced a clinically important benefit.
Blood vitamin D status increased substantially more in the intervention arm. By contrast, interleukin-1 beta, interleukin-6 and high-sensitivity C-reactive protein showed no significant treatment effect in the reported comparisons. The final between-group P values were .76, .31 and .18 respectively. These are selected circulating markers, not a complete measurement of inflammation throughout the body or brain.
This finding bears directly on Vitamin D and Inflammatory Signalling. The measured inflammatory changes did not explain the symptom pattern in this dataset. However, the investigators did not run a formal mediation analysis demonstrating that the effect was independent of every inflammatory process. Different tissues, unmeasured mediators or other sampling times remain outside the test.
How much confidence does the trial support?
The registered primary outcome was the increase in 25-hydroxyvitamin D; depression and inflammatory outcomes were secondary. The ClinicalTrials.gov record NCT03766074 was first submitted in December 2018, after the stated May 2018 start. The protocol was published in 2019. These records help identify the study, but do not establish prospective registration before recruitment began.
The trial used several outcomes and within-group and between-group comparisons, without a clear family-wide multiplicity adjustment. Small samples and variable biomarker measurements constrain the null inflammatory findings. The study offers a positive symptom signal deserving further testing, rather than a definitive estimate for all people with depression.
The protocol’s neurotransmitter objectives also do not establish neurotransmitter results in this particular report. A related publication from the same parent trial would not constitute an independent replication. Cortisol, HPA-axis function and brain serotonin were not measured in the 2022 paper. The broader systems discussed in Vitamin D and Stress Physiology should not be inserted as observed mediators.
The population study: abuse history, status and genetics
Bonk and colleagues analysed two population samples from northeastern Germany. The retained genetic and phenotype samples were 1,997 in SHIP-LEGEND and 2,939 in SHIP-TREND, totalling 4,936. Measured serum vitamin D was available only in TREND, for 2,901 people. The larger combined number must not be attached to a claim about measured blood status.
Childhood abuse was assessed retrospectively using questionnaire reports of emotional, physical or sexual abuse. Lifetime major depressive disorder was assessed by diagnostic interview. Current symptom scores came from BDI-II in LEGEND and PHQ-9 in TREND; TREND scores were converted to a BDI-II metric for analysis. They were not directly measured using the same symptom instrument in both cohorts.
The study examined a serotonin-transporter-related genetic grouping, 5-HTTLPR, and a vitamin-D-binding-protein-related variant, rs4588. Neither genotype is a direct measurement of serotonin activity. Vitamin D Genetics provides the broader genetic context, while Vitamin D Binding Protein Explained explains the carrier-protein subject. The rs4588 variant accounted for only 0.25% of measured vitamin D variance in TREND, making it a weak proxy for status in this dataset.
The interaction result and its important limits
For current symptoms in the measured-status TREND analysis, the three-way interaction involving abuse, 5-HTTLPR and vitamin D grouping had a coefficient of -3.55 and P=.043. The paper’s narrative gives a 95% confidence interval ending at -0.10, whereas Table 2 prints an upper end of +0.10. That disagreement should not be silently resolved in favour of the stronger result.
The authors’ figure shows higher transformed symptom scores among abused SL/SS participants in the low-status group than in the higher-status group. This is a descriptive subgroup pattern, not the expected improvement from supplementation. The study-specific low-status split was below 17.2 ng/mL; it was not established experimentally as a treatment threshold.
The corresponding measured-status three-way interaction for lifetime major depressive disorder was not significant: odds ratio .97, 95% confidence interval .31-2.97, P=.951. This null result is crucial. The current-symptom finding does not automatically extend to the lifetime diagnostic outcome.
Models included demographic and genetic covariates; measured-status models also considered body mass index, physical activity, smoking and season. Such adjustments reduce some alternative explanations but do not remove reverse causation, imperfect recall or every common cause. Several outcomes and interaction terms were explored without a comprehensive reported multiplicity correction.
Genetic-proxy findings were a different analysis
Using rs4588 as a proxy, the three-way interaction for lifetime depression was significant in LEGEND and in the combined analysis. In TREND, the two-sided P value was .088. The authors described a significant one-sided replication, but that is not the same as meeting the conventional two-sided .05 threshold.
This was also not an exact replication of the measured-vitamin-D/current-symptom finding: both the exposure representation and the outcome differed. Combining two cohorts supplies a pooled result, not a third independent cohort. An interaction odds ratio is not a universal percentage reduction in depression risk and is not a treatment effect.
No full Mendelian-randomisation analysis established causal supplementation effects. Proposed explanations involving free vitamin D, receptor function or brain serotonin were not measured as mediating pathways here. Vitamin D Response is useful background for separating a status marker from a demonstrated biological response.
What the two studies contribute together
The trial provides a short-term symptom result alongside null results for three circulating inflammatory markers. The population study shows that status, abuse history, genotype and the choice of depression outcome can produce different association patterns. Their joint value is to make the questions more precise, rather than to assemble a single proven mechanism.
The brain-level implications remain hypotheses. Vitamin D and Brain supplies a broader physiological setting, but neither study directly measured a neural circuit. A clinical symptom can change without identifying its mediator, and an observational interaction can be interesting without establishing a preventive intervention.
The trial reported research-institute funding and no competing interests. Bonk and colleagues disclosed public research support and relevant industry relationships for one author, including travel or speaker payments and research funding. Such disclosures belong in interpretation; they do not by themselves establish bias or misconduct.
Conclusion
Kaviani’s trial reported greater depression-score improvement with its vitamin D regimen, subject to important sample-flow and reporting limitations. It did not show a significant change in the three measured inflammatory markers. Bonk’s findings were exploratory, observational and outcome-dependent, with important null results. Neither paper establishes a complete stress-inflammatory-serotonin mechanism or a personalised prevention or treatment plan.
Scientific sources
Kaviani M, et al. Effects of vitamin D supplementation on depression and some selected pro-inflammatory biomarkers: a double-blind randomized clinical trial. BMC Psychiatry. 2022;22:694. DOI 10.1186/s12888-022-04305-3; PMID 36368945.
Bonk S, Hertel J, Zacharias HU, et al. Vitamin D moderates the interaction between 5-HTTLPR and childhood abuse in depressive disorders. Scientific Reports. 2020;10:22394. DOI 10.1038/s41598-020-79388-7; PMID 33372187.
Kaviani M, et al. Effects of Vitamin D Supplementation on Depression Status, Selected Pro-inflammatory Biomarkers and Neurotransmitters in Depressive Patients: A Study Protocol. Nutrition and Food Sciences Research. 2019;6(4):1-7. DOI 10.29252/nfsr.6.4.1.
ClinicalTrials.gov. Vitamin D Supplementation in Patients With Depression. Trial registration, NCT03766074; current record, not a separate trial.
Related reading
A Systematic Review of Vitamin D during Pregnancy and Postnatally and Symptoms of Depression in the Antenatal and Postpartum Period from Randomized Controlled Trials and Observational Studies
Depression is a common mood disorder associated with childbirth and is hypothesized to be affected by low vitamin D.
Original paper ↗Read more →Association between first-trimester serum 25(OH)D and EPDS-positive postpartum depressive symptoms in women with gestational diabetes mellitus: a retrospective cohort study
This study investigated the association between first-trimester serum 25-hydroxyvitamin D [25(OH)D] concentrations and Edinburgh Postnatal Depression Scale (EPDS)-positive postpartum depressive symptoms in women with GDM.
Original paper ↗Read more →Association between vitamin D deficiency and the 8-year risk of incident depression in patients with rheumatoid arthritis: a cohort study
Negative and positive control outcomes were also examined.
Original paper ↗Read more →Association between vitamin D levels and depression among type 2 diabetes mellitus patients in the Southern Region of Malaysia
this cross-sectional study investigated the relationship between serum vitamin D levels and depression among 330 T2DM patients in Johor, Malaysia.
Original paper ↗Read more →Associations Between Vitamin D Levels and Depressive Symptoms in Later Life: Evidence From the English Longitudinal Study of Ageing (ELSA)
We investigated the cross-sectional associations between serum 25-hydroxyvitamin D (25OHD) levels and depressive symptoms (CES-D) in 5,607 older adults from the English Longitudinal Study of Ageing (ELSA).
Original paper ↗Read more →Biochemical Associations with Depression, Anxiety, and Stress in Hemodialysis: The Role of Albumin, Calcium, and β2-Microglobulin According to Gender
This study examined the link between depression, anxiety, and stress in hemodialysis patients and a broad range of biochemical markers, focusing on gender as a main factor.
Original paper ↗Read more →Decision-making process in the pre-dialysis CKD patients: do anxiety, stress and depression matter?
Demographic, clinical, and laboratory data were evaluated.
Original paper ↗Read more →Depression in patients with knee osteoarthritis: risk factors and associations with joint symptoms
Three hundred ninety-seven participants were selected from a randomized controlled trial in people with symptomatic knee OA and vitamin D deficiency (age 63.3 ± 7.1 year, 48.6% female).
Original paper ↗Read more →Dietary and supplemental vitamin D intake and pain interference in adults with chronic spine-related pain: a cross-sectional survey study
This study evaluated the associations between dietary vitamin D exposure ranking, vitamin D supplementation, and pain-related functional interference among adults in tertiary care settings.
Original paper ↗Read more →Does Vitamin D3 Supplementation Improve Depression Scores among Rural Adolescents? A Randomized Controlled Trial
The objective of this study was to assess the effect of vitamin D supplementation on depression scores among rural adolescents.
Original paper ↗Read more →Effects of vitamin D supplementation on depression and some selected pro-inflammatory biomarkers: a double-blind randomized clinical trial
An 8-week double-blind randomized clinical trial (RCT) was performed on 56 (18 to 60 yrs) patients with mild to moderate depression, randomly assigned to intervention (50,000 IU cholecalciferol 2wks−1) and control (placebo) groups.
Original paper ↗Read more →Husband involvement in antenatal care moderates the link between vitamin D status and depressive symptoms in pregnant women
Recognizing the significance of the husband’s participation in antenatal care, this study aimed to examine whether the husband’s involvement moderates the link between the mother’s vitamin D status and depressive symptoms during pregnancy.
Original paper ↗Read more →Improvement in Symptoms of Depression and Anxiety and Cardiometabolic Risk Factors in Children and Adolescents with Overweight and Obesity Following the Implementation of a Multidisciplinary Personalized Lifestyle Intervention Program
Childhood obesity is one of the most challenging contemporary public health problems.
Original paper ↗Read more →Maternal depression attenuates newborn vitamin D concentrations in winter-spring: a prospective population-based study
We aimed to investigate whether the newborns of mothers with maternal depression (MD) had lower vitamin D levels than newborns of non-MD (NMD) mothers and identify the potential mechanism underlying this association.
Original paper ↗Read more →Mendelian randomization studies of depression: evidence, opportunities, and challenges
Major depressive disorder (MDD) poses a significant social and economic burden worldwide.
Original paper ↗Read more →Molecular Basis Underlying the Therapeutic Potential of Vitamin D for the Treatment of Depression and Anxiety
Major depressive disorder and anxiety disorders are common and disabling conditions that affect millions of people worldwide.
Original paper ↗Read more →Relationship Between Vitamin D Deficiency and Postpartum Depression
To overcome these limitations, future studies should aim for more standardized methodologies and randomized controlled trials to establish causality and effective interventions.
Original paper ↗Read more →Serum 25-Hydroxyvitamin D Concentrations and Depressive Symptoms among Young Adult Men and Women
Our aim was to investigate the association between vitamin D status and depressive symptoms in a non-clinical young adult sample living in Dunedin, New Zealand.
Original paper ↗Read more →Sexual Function and Depressive Symptoms in Metformin-Treated Women with Drug-Induced Hyperprolactinemia and Different Vitamin D Status: A Pilot Study
Therefore, the present study aimed to examine whether vitamin D status modulates the effects of metformin, a medication with less pronounced prolactin-lowering properties, on sexual function and depressive symptoms.
Original paper ↗Read more →The prevalence of educational burnout, depression, anxiety, and stress among medical students of the Islamic Azad University in Tehran, Iran
Psychological disorders have negative consequences on students’ learning and academic performance.
Original paper ↗Read more →The relationship between dietary lipophilic index and load with depression, anxiety, and stress symptoms
This study aimed to determine the relationship between dietary LI and LL with symptoms of depression, anxiety and stress.
Original paper ↗Read more →Original sources
Effects of vitamin D supplementation on depression and some selected pro-inflammatory biomarkers: a double-blind randomized clinical trial
Published in BMC Psychiatry (2022).
Publication details
Kaviani M, et al. Effects of vitamin D supplementation on depression and some selected pro-inflammatory biomarkers: a double-blind randomized clinical trial. BMC Psychiatry. 2022;22:694. DOI 10.1186/s12888-022-04305-3; PMID 36368945.
Vitamin D moderates the interaction between 5-HTTLPR and childhood abuse in depressive disorders
Published in Scientific Reports (2020).
Publication details
Bonk S, Hertel J, Zacharias HU, et al. Vitamin D moderates the interaction between 5-HTTLPR and childhood abuse in depressive disorders. Scientific Reports. 2020;10:22394. DOI 10.1038/s41598-020-79388-7; PMID 33372187.
Effects of Vitamin D Supplementation on Depression Status, Selected Pro-inflammatory Biomarkers and Neurotransmitters in Depressive Patients: A Study Protocol
Published in Nutrition and Food Sciences Research (2019).
Publication details
Kaviani M, et al. Effects of Vitamin D Supplementation on Depression Status, Selected Pro-inflammatory Biomarkers and Neurotransmitters in Depressive Patients: A Study Protocol. Nutrition and Food Sciences Research. 2019;6(4):1-7. DOI 10.29252/nfsr.6.4.1.
Vitamin D Supplementation in Patients With Depression
ClinicalTrials.gov. Vitamin D Supplementation in Patients With Depression.
Publication details
ClinicalTrials.gov. Vitamin D Supplementation in Patients With Depression. Trial registration, NCT03766074; current record, not a separate trial.